论文部分内容阅读
目的:探讨膀胱肿瘤电切术后应用吉西他滨行膀胱灌注化疗的效果及对肿瘤标志物和生命质量的影响。方法:选择浙江省宁波市医疗中心李惠利东部医院2016年1月至2018年3月接诊且行经尿道膀胱肿瘤电切术治疗的膀胱癌患者105例为研究对象，按照随机数字表法分为观察组53例与对照组52例。观察组采用吉西他滨治疗，对照组采用盐酸表柔比星治疗。两组疗程均为每周1次，共6次，再以每个月1次，连续12次。比较两组复发情况、不良反应发生情况、治疗前后肿瘤标志物和生命质量变化。结果:观察组复发率低于对照组[1.89%（1/53）比15.38%（8/52）]，差异有统计学意义（n χ2=4.501，n P<0.05）。观察组不良反应发生率低于对照组[9.43%（5/53）比30.77%（16/52）]，差异有统计学意义（n χ2=7.467，n P<0.05）。两组治疗后血清癌胚抗原（CEA）、细胞角蛋白19（CK19）和癌抗原199（CA199）水平较治疗前降低，并且观察组治疗后血清CEA、CK19和CA199水平低于对照组，差异均有统计学意义（n P<0.05）。两组治疗后Karnofsky功能状态（KPS）评分较治疗前增加，并且观察组治疗后KPS评分高于对照组，差异有统计学意义（n P<0.05）。n 结论:膀胱肿瘤电切术后应用吉西他滨行膀胱灌注化疗效果良好，可降低复发率和不良反应发生，降低CEA、CK19和CA199水平，提高患者生命质量。“,”Objective:To investigate the effect of gemcitabine intravesical instillation chemotherapy on bladder cancer markers and quality of life after resection of bladder cancer.Methods:One hundred and five patients with bladder cancer who received transurethral resection of bladder cancer from January 2016 to March 2018 in Li Huili Eastern Hospital of Ningbo Medical Center were randomly divided into observation group (53 cases) and control group (52 cases) according to random number table method. The observation group was treated with gemcitabine, while the control group was treated with epirubicin hydrochloride. The two groups were treated once a week for 6 times and once a month for 12 consecutive times. Recurrence, adverse reactions, changes of tumor markers and quality of life before and after treatment were compared between the two groups.Results:The recurrence rate of the observation group was lower than that of the control group: 1.89%(8/52) vs. 15.38%(16/52), there was significant difference (n P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group: 9.43%(5/53) vs. 30.77%(16/52), there was significant differences (n P<0.05). After treatment, the serum carcino-embryonic antigen (CEA), cytokeratin (CK)19 and cancer antigen (CA) 199 levels in the two groups were lower than those before treatment, there were significant differences (n P<0.05); after treatment, the serum CEA, CK19 and CA199 levels in the observation group were lower than those in the control group (n t=10.938, 13.601, 9.330, n P<0.05). The scores of Karnofsky performance status scale (KPS) of the two groups increased after treatment, there was significant difference (n P<0.05); the scores of KPS of the observation group was higher than that of the control group after treatment, there was significant difference (n t=5.740, n P<0.05).n Conclusions:Gemcitabine intravesical instillation chemotherapy is effective in patients with bladder cancer after resection. It can reduce recurrence and adverse reactions, reduce CEA, CK19 and CA199 levels, and improve the quality of life of patients.